The latest breakthrough in cell-based therapies for multiple sclerosis has scientists abuzz with excitement. A team of researchers at Johns Hopkins University School of Medicine has successfully used magnetic particle imaging (MPI) to track the movement of therapeutic cells in mice, a crucial step towards personalizing treatments for patients.
At its core, MPI is an advanced imaging technique that allows investigators to visualize where therapeutic cells end up in the body. In this study, researchers led by Dr. Jeff Bulte injected mesenchymal stem cells (MSCs) into the bloodstream of healthy mice and tracked their movement using MPI. The results were striking: MSCs moved differently through the body than they did in mice with experimental autoimmune encephalomyelitis (EAE), a lab-induced immune condition commonly used to model multiple sclerosis.
The study, published in Science Advances, marks a significant milestone in the development of cell-based therapies for MS. Currently, there is a major obstacle to their use: researchers and clinicians have no way of tracking where the cells actually go once they are injected into the body. MPI aims to solve this problem by labeling therapeutic cells with magnetically-charged nanoparticles and using a specialized scanner to track the movement of these particles.
But what does this mean for patients? According to Dr. Ali Shakeri-Zadeh, first author of the study, selecting different cell types can help researchers compare the effect of cell size and delivery route for cell therapy treatments. In other words, by tracking the movement of cells in mice with EAE, scientists can gain insights into how these therapies might work in humans.
The results were fascinating: MSCs accumulated in two organs - the lungs and liver - in both healthy and EAE mice. However, there was a key difference between the two groups: in mice with EAE, MSCs also accumulated in the spleen, an organ that plays important roles in regulating immune function.
According to the researchers, this accumulation of MSCs in the spleen is consistent with the idea that these stem cells may help modulate the activity of inflammation-driving immune cells in MS. Using MPI to track these cells' movements "may open the door to correlating splenic stem cell load with disease severity, [immune activity], and therapeutic outcomes," they wrote.
In other words, by tracking where MSCs go in patients with MS, researchers may be able to identify biomarkers that predict treatment response or even monitor treatment effectiveness. This could ultimately lead to more personalized treatments for patients with MS.
As Dr. Shakeri-Zadeh noted, "in autoimmune diseases, particularly MS, it's thought that harmful immune cells ... are released from the spleen." The accumulation of MSCs in the spleen of mice with EAE suggests that these stem cells may be able to subdue these harmful immune cells right at the source.
In the end, this study marks a crucial step towards developing cell-based therapies for multiple sclerosis. By tracking where therapeutic cells go in patients with MS, researchers may be able to identify new targets for treatment and develop more effective treatments. As Dr. Bulte noted, "using MPI, we can visualize where therapeutic cells end up in the body." And that could ultimately lead to a more precise dose of cell therapy for individual patients.
Written by: Slick Manchetz | The Citizen Edition
“Reality's a joke, folks.”